Modulating Ciliogenesis via Chromatin Complex Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic obstructive pulmonary disease (COPD) is characterized by inefficient mucociliary clearance due to loss of ciliated cells, leading to severe symptoms and high mortality, as the abnormal bronchial epithelium fails to clear airway mucus, bacteria, and debris effectively.
Innovation Solution
Compounds that bind or interact with chromatin remodeling complexes, such as Polycomb Repressor Complex 1 (PRC1) and Trithorax group-MLL (TrxG-MLL), are used to modulate ciliogenesis, acting as an 'on/off' switch for ciliogenesis in the human bronchial epithelium, thereby treating or preventing aberrant or defective ciliogenesis-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds bind to chromatin remodeling complexes (PRC1/TrxG-MLL) to modulate ciliogenesis, then ciliogenesis is restored/enhanced in COPD patients, but the complexity of the treatment mechanism increases
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to modulate the interaction between R2R1 protein and chromatin remodeling complexes (PRC1/TrxG-MLL). These compounds act as mediators that can enhance or inhibit ciliogenesis by affecting the R2R1-chromatin complex interaction, thereby providing a controllable way to restore ciliogenesis in COPD patients without directly manipulating the complex protein-protein interactions
Solution Approach 2:
The patent employs compounds that can change the functional state of chromatin remodeling complexes by binding to them or their associated proteins (R2R1). By modifying parameters such as chromatin accessibility, histone modification states, or protein interaction dynamics, the compounds enable controlled modulation of ciliogenesis, transforming a complex biological process into a regulatable therapeutic effect
2Ease of operation
If R2R1 protein interaction with PRC1/TrxG-MLL complexes is modulated to control ciliogenesis, then ciliogenesis can be switched on/off, but the difficulty of detecting and measuring the mechanism increases
Solution Approach 1:
The patent utilizes compounds that can induce detectable changes in the system, potentially through fluorescent tagging or colorimetric assays associated with chromatin remodeling activity. By linking ciliogenesis modulation to observable physical changes (such as fluorescence intensity, color change, or other detectable signals), the mechanism becomes measurable and monitorable, bridging the gap between molecular interaction and detectable output
3Adaptability or versatility
If compounds target specific chromatin binding/remodeling complexes to treat COPD, then treatment specificity is improved, but the precision of targeting required increases
Solution Approach 1:
The patent employs compounds with specific molecular structures designed to bind preferentially to particular chromatin remodeling complexes (PRC1 or TrxG-MLL) or their interaction interfaces with R2R1. By optimizing local molecular properties such as binding affinity, specificity constants, and structural complementarity, the compounds achieve high targeting precision for specific complexes while maintaining versatility in treating different COPD cases through selective modulation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The disclosure is based on the finding that compounds capable of binding to (or interacting with) chromatin binding/remodelling complexes (for example Polycomb group PRC1 and Trithorax group MLL) and/or modulation of the same can be used to modulate (for example switch on/off) ciliogenesis as may occur, for example, in the human pulmonary bronchial epithelium. Provided are compounds, compositions, methods and medicaments which may be used to treat and/or prevent diseases and/or conditions associated with aberrant or defective ciliogenesis.